Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CES1 | P23141 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21202371 | 0.85 | ALDH1A1 (0.44) | NPC1RAB9ASMN1; SMN2CES1KMT2A | |
| SCHEMBL23320163 | 0.82 | PARP1 (0.40) | NPC1RAB9ASMN1; SMN2CES1KMT2A | |
| SCHEMBL17288477 | 0.82 | MEN1 (0.53) | NPC1RAB9ASMN1; SMN2CES1KMT2A | |
| SCHEMBL2317970 | 0.80 | CES1 (0.40) | SMN1; SMN2CES1KMT2AFAAHTDP1 | |
| SCHEMBL17183897 | 0.80 | CES1 (0.40) | CES1KMT2AFAAHTDP1L3MBTL1 | |
| SCHEMBL10150911 | 0.79 | FAAH (0.44) | NPC1RAB9ASMN1; SMN2MMEL1FAAH | |
| SCHEMBL24462346 | 0.79 | APEX1 (0.38) | NPC1RAB9ASMN1; SMN2CES1KMT2A | |
| SCHEMBL20239528 | 0.79 | ALDH1A1 (0.43) | NPC1RAB9ACES1FAAHALDH1A1 | |
| SCHEMBL1912564 | 0.78 | NLRP3 (0.46) | NPC1RAB9AKMT2AL3MBTL1MEN1 | |
| SCHEMBL24462319 | 0.78 | CES1 (0.36) | CES1KMT2AFAAHTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | disclosed |
| CN-114401952-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3962899-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20210401808-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210401808-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-12-30 | — | — | US | disclosed |
| US-20210363136-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-11-25 | — | — | US | disclosed |
| US-11033533-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136493-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-7612070-B2 | Heterocyclic compounds as antiinflammatory agents and cyclooxygenase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612070-B2 | Heterocyclic compounds as antiinflammatory agents and cyclooxygenase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-11-03 | — | — | US | disclosed |
| US-4785012-A | OXAZOLE DERIVATIVES CONTAINING ALCOHOLS OR ESTERS | SYNTEX CORPORATION (US) | 1988-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363136-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | NPC1 1292/4885RAB9A 2923/4885SMN1; SMN2 2611/4885 |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | NPC1 249/4885RAB9A 3095/4885SMN1; SMN2 1020/4885 |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | NPC1 325/4885RAB9A 2855/4885SMN1; SMN2 456/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | NPC1 1292/4885RAB9A 2923/4885SMN1; SMN2 2611/4885 |
| US-20210401808-A1 | (2R,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-HYDROXY-4-[(5-METHYLOXAZOLE-2-CARBONYL)AMINO]PENTANOIC ACID | MME, DNPEP, TMPRSS15 | NPC1 829/4885RAB9A 4537/4885SMN1; SMN2 1432/4885 |
| US-11033533-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | MME, DNPEP, TMPRSS15 | NPC1 801/4885RAB9A 4492/4885SMN1; SMN2 1410/4885 |
| US-11642332-B2 | (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | MME, DNPEP, TMPRSS15 | NPC1 801/4885RAB9A 4492/4885SMN1; SMN2 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.